Trustees of Dartmouth College
Trial Pipeline
Table-Top Water Pitcher to Reduce Arsenic Exposure Among Well Users in New Hampshire
NCT07103356
Virtual Contexts for Affective Modulation
NCT06986122
Neural Mechanisms of Interpersonal Expectations on Negative Affect
NCT06980090
Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use
NCT06920238
Genetic Risk, Parental Feeding Practices, and Appetitive Traits in Early Life
NCT06534541
Transcranial Direct Current Stimulation and Modulation of Affect and Pain
NCT06989749
Effects of Social Feedback on Intracranial EEG
NCT06975800
Improving Implementation of Evidence-based Approaches and Surveillance to Prevent Bacterial Transmission and Infection
NCT04600973
The Warmth, Anticipation, Sensation, Aversion, and Body-part Imaging Study
NCT04653064
Adapting a Mammography Decision Aid to Support Women Living in a Community Contaminated by PFAS
NCT06098118
CanCope: Digital Intervention for Coping With Cannabis Craving
NCT05328362
Sweetgoals for Type 1 Diabetes
NCT04646473
Effects of Expectations on Negative Affect, Perceived Cognitive Effort, and Pain
NCT05425563
Trial on the Effect of E-cigarette Advertising on Cigarette Perceptions in Adolescents
NCT03786042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
What the Pipeline for Trustees of Dartmouth College Shows
According to the ClinicalTrials.gov registry, Trustees of Dartmouth College is linked to 14 US clinical trials across every stage of research activity. Of those, 9 studies are currently recruiting — about 64% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 36% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Trustees of Dartmouth College reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Trustees of Dartmouth College is Expectations with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.